» Articles » PMID: 38634993

Assessment of ICD Eligibility in Non-ischaemic Cardiomyopathy Patients: A position Statement by the Task Force of the Dutch Society of Cardiology

Abstract

International guidelines recommend implantation of an implantable cardioverter-defibrillator (ICD) in non-ischaemic cardiomyopathy (NICM) patients with a left ventricular ejection fraction (LVEF) below 35% despite optimal medical therapy and a life expectancy of more than 1 year with good functional status. We propose refinement of these recommendations in patients with NICM, with careful consideration of additional risk parameters for both arrhythmic and non-arrhythmic death. These additional parameters include late gadolinium enhancement on cardiac magnetic resonance imaging and genetic testing for high-risk genetic variants to further assess arrhythmic risk, and age, comorbidities and sex for assessment of non-arrhythmic mortality risk. Moreover, several risk modifiers should be taken into account, such as concomitant arrhythmias that may affect LVEF (atrial fibrillation, premature ventricular beats) and resynchronisation therapy. Even though currently no valid cut-off values have been established, the proposed approach provides a more careful consideration of risks that may result in withholding ICD implantation in patients with low arrhythmic risk and substantial non-arrhythmic mortality risk.

Citing Articles

2021 European Society of Cardiology guidelines on cardiac pacing and cardiac resynchronisation therapy : Statement of endorsement by the NVVC.

Maass A, Tuinenburg A, Mairuhu G, Faes M, Klinkenberg T, Ruigrok S Neth Heart J. 2025; 33(2):38-45.

PMID: 39836347 PMC: 11757831. DOI: 10.1007/s12471-024-01927-y.

References
1.
Mullens W, Auricchio A, Martens P, Witte K, Cowie M, Delgado V . Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. Europace. 2021; 23(8):1324-1342. DOI: 10.1093/europace/euaa411. View

2.
Schrage B, Uijl A, Benson L, Westermann D, Stahlberg M, Stolfo D . Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry. Circulation. 2019; 140(19):1530-1539. DOI: 10.1161/CIRCULATIONAHA.119.043012. View

3.
Shen L, Jhund P, Petrie M, Claggett B, Barlera S, Cleland J . Declining Risk of Sudden Death in Heart Failure. N Engl J Med. 2017; 377(1):41-51. DOI: 10.1056/NEJMoa1609758. View

4.
Zweerink A, Friedman D, Klem I, van de Ven P, Vink C, Biesbroek P . Size Matters: Normalization of QRS Duration to Left Ventricular Dimension Improves Prediction of Long-Term Cardiac Resynchronization Therapy Outcome. Circ Arrhythm Electrophysiol. 2018; 11(12):e006767. DOI: 10.1161/CIRCEP.118.006767. View

5.
Wong C, Chaudhry S, Desai M, Krumholz H . Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med. 2011; 124(2):136-43. PMC: 3237399. DOI: 10.1016/j.amjmed.2010.08.017. View